HS Pipeline Watch: Sonelokimab Demonstrates High HiSCR75 and HiSCR100 Rates at Week 40

Sonelokimab (MoonLake Immunotherapeutics) produced continued improvement of Hidradenitis Suppurativa Clinical Response (HiSCR) scores and patient-reported outcomes at Week 40 in the Phase 3 VELA clinical trials of patients with moderate-to-severe hidradenitis suppurativa (HS), which were presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.

Specifically, 62% of patients with moderate-to-severe HS treated with sonelokimab achieved HiSCR75, and 32% achieved HiSCR100 at Week 40. These results were consistent across both trials in the VELA Program.

Sonelokimab, an investigational Nanobody under development for the treatment of inflammatory disease, inhibits interleukin (IL)-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.

“The Week 40 results from the VELA trials show an early and increasing clinical benefit over time for patients treated with sonelokimab, addressing a critical goal in HS treatment: long-term disease control,” says Alexa Kimball, MD, MPH, President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center and a Professor of Dermatology at Harvard Medical School in Boston, MA, in a news release. “The consistency of the VELA data over time reinforces the opportunity for sonelokimab to address this important unmet need for patients living with HS.”

The Phase 3 VELA program in adults with moderate-to-severe HS used the higher clinical response level of HiSCR 75 as the primary endpoint. Key secondary endpoints included the change from baseline in the HS Quality of Life score (HiSQOL) as well as other scores, including the percentage of participants achieving at least a 55% reduction in the International HS Severity Scoring System (IHS4-55), the percentage of participants achieving at least a three-point improvement from baseline in the worst skin pain Numerical Rating Scale (NRS) among participants with a baseline score of at least three points, and the percentage of patients achieving a Dermatology Life Quality Index (DLQI) total score improvement of ≥4 (minimal clinically important difference), among participants with a baseline DLQI ≥4.

A total of 838 patients were enrolled across both trials. Following the primary endpoint at Week 16, patients in the placebo arm were switched to receive sonelokimab treatment for the remaining duration of the trial until Week 52. Patients originally randomized to the sonelokimab arm continued to receive sonelokimab at the monthly 120mg maintenance dose. All patients have completed Week 40, and discontinuation rates were at the low end of those observed in other pivotal HS trials. After Week 52, patients could switch into a two-year open-label extension trial.

Up to 77% of patients achieved an IHS-4 55 response, and up to 25% of patients achieved inflammatory remission at Week 40, which was defined as a 100% reduction in abscesses (A100), nodules (N100), and draining tunnels (DT100).

These long-term clinical responses were accompanied by continued improvement in patient-reported outcomes. Patients treated with sonelokimab showed a significant improvement in HiSQOL score at Week 40. While 59% of patients were within the “very severe” category on the HiSQOL severity score at baseline, 63% of patients were in the “mild / none” category at Week 40, according to pooled results. Improvements vs. baseline in HiSQOL-Mini items ranged from 41% (pain), to 54% (walking, getting dressed), to 62% (down or depressed) at Week 40, the study showed.

In addition, up to 43% of patients experienced a marked reduction of pain, as measured by an at least three-point improvement from baseline in the worst skin pain NRS. Fully 65% of patients achieved a meaningful (at least four points from baseline) improvement in DLQI.

The safety profile of sonelokimab in the VELA clinical trials remains consistent over time, with no new safety signals detected.

What’s Next for Sonelokimab in HS?

MoonLake Immunotherapeutics plans to release 52-week data of the VELA-1 and VELA-2 in Q2 2026, with a Biologics License Application submission planned in the second half of 2026.

PHOTO CREDIT: DermNet